New Research in Cancer Treatment: Recent studies indicate that medical professionals could enhance cancer cure rates by altering treatments proactively, rather than waiting for tumors to regrow post-initial therapy. The innovative approach suggests swapping treatments while the tumor is still decreasing in size.
This method aims to tackle one of the most significant challenges in cancer therapy: drug resistance.
Why Cancer Recurrence is Common
Led by Dr. Robert Noble, a senior lecturer in Mathematics at St George’s, University of London, the study uncovers startling insights.
“While treatments may lead to tumor shrinkage, there’s a high likelihood of regrowth. This recurrence happens because a small fraction of cancer cells develop mutations that confer treatment resistance,” he explains.
A mutation refers to a change in a cell’s genetic code, often occurring randomly during cell division. If such a mutation allows a cell to survive a drug that is lethal to other tumor cells, that resistant cell may proliferate, allowing its descendants to reconstruct the tumor.
Traditionally, physicians continue the initial treatment until tests show renewed cancer growth, after which they typically transition to an alternative medication.
The issue with this approach is that letting visible recurrence happen extends the window for surviving cancer cells to evolve. By the time a second treatment is initiated, certain cells might already harbor mutations that render them impervious to this new therapy.
Employing Proactive Treatment Changes
Based on evolutionary theory, a different strategy emerges.
Instead of waiting for the initial treatment to lose effectiveness, healthcare providers can transition to a secondary treatment whilst the tumor is still responding. This strategy is likened to a “kick while you’re falling.”
This approach could be especially beneficial for cancers where initial treatments frequently fail due to resistance.
Introducing early treatment changes can complicate things for resistant cancer cells, as each new therapy presents distinct challenges, potentially impeding their ability to adapt.
As Dr. Noble conveys in a podcast, “Evolutionary strategies have proven effective in various contexts, such as tackling antibiotic resistance or determining which flu vaccine to administer in a season. There is significant potential for similar methodologies to be applied in cancer treatments.”
Like antibiotic resistance, the evolution of cancer cells follows a comparable process. Surviving bacteria can reproduce and transmit their resistance to subsequent generations. Similarly, scientists are analyzing the evolution of influenza viruses to decide which strains to target for annual vaccinations.
Researchers advocate that a similar evolutionary perspective could revolutionize cancer therapies.
Utilizing Mathematical Models to Track Tumor Evolution
Dr. Noble and his team adapted mathematical tools typically reserved for studying environmental pressures on species to investigate this hypothesis.
In this context, each cancer treatment functions as a form of environmental stress, eliminating vulnerable cells while allowing those with advantageous resistance mutations to thrive. Mathematical models help predict the survival and growth rates of different cancer cell populations based on various treatment schedules.
The findings indicate that early treatment switches may yield better outcomes compared to the conventional method.
However, these findings primarily stem from mathematical modeling and necessitate further testing through lab experiments and patient trials.
Three small clinical trials are currently being conducted for soft tissue cancer, prostate cancer, and breast cancer, with additional tests in the pipeline.
Targeting Larger Tumors with Multiple Treatments
The model also illustrates that relying on just two treatments may fall short in many scenarios.
“Our model suggests this innovative strategy will generally outperform standard treatment,” notes Dr. Noble. “Two sequential treatments, even if well-timed, may only achieve success in relatively small tumors. However, there’s a promising potential that alternating between three or more treatments, based on the same principles, can help eliminate larger tumors.”
Employing multiple treatment options exposes cancer cells to a variety of pressures, complicating their ability to develop a fully resistant population.
Nonetheless, this approach might not be universally effective for all patients or cancer types. Selection of treatments must consider tumor type, size, available medications, and patient health. Researchers still need to pinpoint the safest and most effective timing for each treatment switch.
Ultimately, this study opens avenues for rethinking cancer management. Rather than merely reacting to treatment failures, doctors might one day anticipate resistance patterns and act preemptively before tumors can recover.
The full research paper will be featured in the journal Genetics.
Dr. Noble collaborated with an international team of mathematical biologists on this research, which stemmed from the final year project of Srishti Patil, a master’s student at the Indian Institute of Science Education and Research in Pune, who spent several months at St George’s University of London under Dr. Noble’s mentorship.
The research team also included Armaan Ahmed, an undergraduate at Johns Hopkins, and Dr. Noble’s longtime collaborator, Dr. Yannick Viosatte from Paris-Dauphine PSL.
Source: www.sciencedaily.com